Company Filing History:
Years Active: 2011
Title: Jesko Koehnke: Innovator in Cancer Treatment
Introduction
Jesko Koehnke, an esteemed inventor based in Oldenburg, Germany, has made significant strides in the field of cancer treatment with his innovative research. With one patent to his name, Koehnke’s work focuses on peptides that selectively target and destroy malignant and transformed mammalian cells.
Latest Patents
Koehnke's patent, titled "Peptides selectively lethal to malignant and transformed mammalian cells," highlights the potential of these peptides in neoplastic disease treatment. The invention provides peptides that correspond to all or a portion of amino acid residues 12-26 of the human p53 protein, which prove lethal to cancerous cells when combined with a membrane-penetrating leader sequence. This groundbreaking work opens new avenues for the development of targeted cancer therapies.
Career Highlights
Koehnke is associated with the Research Foundation of the State University of New York, where he contributes his expertise in biochemistry and molecular biology. His educational background and innovative approaches have established him as a key figure in his field, particularly in the realm of cancer research.
Collaborations
Throughout his career, Koehnke has collaborated with distinguished scientists such as Josef Michl and Matthew R Pincus. Together, they have combined their knowledge and expertise, fostering an environment of innovation that continues to pave the way for advancements in cancer treatment methodologies.
Conclusion
Jesko Koehnke’s contributions to the scientific community through his pioneering patent demonstrate his commitment to fighting cancer. As research continues to evolve, his work may hold the promise of more effective therapies for patients battling malignancies, making him a noteworthy inventor in the realm of medical innovations.